Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Zhang, Zhibo; Fang, Yuan; Chen, Runzhe; Li, Ye; Ma, Junxun; Yan, Xiang; Wang, Lijie; Zhang, Fan; Tao, Haitao; Guo, Dong; Huang, Zhiyue; Zhang, Sujie; Li, Xiaoyan; Zhi, Xiaoyu; Ge, Xiangwei; Hu, Yi; Wang, Jinliang

doi:10.3389/fimmu.2020.01173

Cited by 29 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17] The pretreatment serum CEA or CYFRA 21-1 level was a predictive biomarker of PFS in patients with advanced NSCLC treated with nivolumab. 15,16 Furthermore, a reduction in CEA or CYFRA21-1 levels greater than 20% 33 or a meaningful reduction in > 2 of 4 biomarkers (CEA, CA125, CYFRA21-1, and SCC-Ag), 34 as a dynamic index, may serve as a reliable early marker of high ORR and prolonged PFS and OS. More recently, a decreased leading STM was similarly associated with longer PFS in NSCLC patients treated with monoimmunotherapy, 17 as well as in those treated with chemoimmunotherapy and monoimmunotherapy maintenance.…”

mentioning

confidence: 99%

Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer

Tang¹,

Li²,

Guan³

et al. 2021

CMAR

View full text Add to dashboard Cite

mentioning

confidence: 99%

Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer

Tang¹,

Li²,

Guan³

et al. 2021

CMAR

View full text Add to dashboard Cite

“…Optimization-based method or propensity score matching was intended to be used like our previous study to balance the baseline covariates between the elevated NSE group and normal NSE group. [ 36 , 37 ] However, as the baseline covariates were comparable between the 2 groups, these methods were waived. Taken together, elevated NSE level at baseline was associated with dismal prognosis of SCLC patients with first-line ICIs treatment.…”

Section: Discussionmentioning

confidence: 99%

Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors

Zhang¹,

2021

Medicine

Self Cite

View full text Add to dashboard Cite

There has been no effective biomarker for small cell lung cancer (SCLC) patients with first-line immune checkpoint inhibitors (ICIs) treatment. The predictive value of neuron-specific enolase (NSE) in this cohort remains unclear. The medical records of 254 consecutive SCLC patients receiving programmed cell death receptor-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors were compiled from January 2015 to October 2020 in Chinese PLA General Hospital. Survival analysis was performed to explore the prognostic role of NSE at baseline and 3 weeks post treatment. One hundred two advanced SCLC patients treated with first-line PD-1/PD-L1 inhibitors were enrolled in this study. Normal baseline NSE levels were correlated with significantly prolonged progression-free survival (PFS, median: 8.7 vs 4.7 months, P = .006) and overall survival (OS, median: 23.8 vs 15.2 months, P = .014) compared with elevated baseline NSE levels, so as for normal NSE levels at 3 weeks with prolonged PFS (median PFS: 8.4 vs 4.5 months, P = .0002) and OS (median OS: 23.3 vs 7.4 months, P < .0001). Intriguingly, elevated NSE levels at 3 weeks were associated with shorter PFS (median PFS: 4.5 vs 5.8 months, P = .04) and OS (median OS: 5.5 vs 14.7 months, P < .0001) compared with normal NSE levels in the elevated baseline NSE subgroup. Most subgroup analyses stratified by clinical characteristics confirmed the prognostic value of baseline NSE level. Elevated NSE levels at baseline and 3 weeks were associated with worse prognosis in advanced SCLC patients receiving first-line ICIs treatment. NSE level might be applied as a useful prognostic tool for SCLC patients with immunotherapy.

show abstract

“…The dynamic changes in CEA, CA125, and CYFRA21-1 relative to baseline have prognostic value for patients with advanced NSCLC treated with immunosuppressants [27]. For the diagnosis of lung cancer, although the specificities of CEA, NSE, and CYFRA21-1 are all 95%, their sensitivities are only 15.2%, 17.0%, and 17.9%, respectively [24], while SAA2 has the highest sensitivity (83.61%), outstanding specificity (91.11%) and a high area under the curve (AUC) (0.9252).…”

Section: Discussionmentioning

confidence: 99%

Identification of plasma SAA2 as a candidate biomarker for the detection and surveillance of non-small cell lung cancer

Zhang¹,

Han²,

Xu³

et al. 2021

neo

View full text Add to dashboard Cite

This study aimed to measure the expression of SAA2 in plasma and to assess its diagnostic efficacy as a biomarker for non-small cell lung cancer (NSCLC). The gene expression of SAA2 in NSCLC was analyzed based on a database. Then, SAA2 expression was detected by immunohistochemistry in lung tissue and by enzyme-linked immunosorbent assay in 90 patients with NSCLC and 61 normal controls. Finally, the diagnostic performance was assessed in terms of accuracy, sensitivity, and specificity.At the gene and protein levels, the SAA2 expression was significantly higher in the NSCLC group than in the control group (p < 0.01). It was higher in lung squamous carcinoma than in lung adenocarcinoma and in males than in females, and this trend was also observed in the lung squamous carcinoma group. Of note, the expression of SAA2 increased with increasing disease stage. Receiver operating characteristic (ROC) curve analysis revealed that the sensitivity of SAA2 was 83.61%, the specificity was 91.11%, and the area under the curve (AUC) was 0.9252. Its accuracy was 68.89%, which was higher than that of other conventional diagnostic biomarkers, and the combined application can effectively improve the diagnostic efficiency. Based on the results, SAA2 expression was positively correlated with the disease stage of NSCLC. Notably, SAA2 is more concerning in male patients with lung squamous carcinoma, and it can help in the screening and diagnosis of NSCLC. SAA2 may represent a novel diagnostic biomarker in NSCLC.

show abstract

Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Abstract: Conclusions:The dynamic change of CEA, CA125, CYFRA21-1, and SCC-Ag from baseline have prognostic value for late-stage NSCLC patients treated with PD-1/PD-L1 inhibitors. Decrease of associated biomarkers serum levels were associated with favorable clinical outcomes.

Cited by 29 publications

References 40 publications

Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer

Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer

Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors

Identification of plasma SAA2 as a candidate biomarker for the detection and surveillance of non-small cell lung cancer

Contact Info

Product

Resources

About